百奥赛图（北京）医药科技股份有限公司

About 百奥赛图（北京）医药科技股份有限公司

Biocytogen is committed to developing innovative antibody drugs that meet patient needs, focusing on multiple disease areas such as oncology, autoimmune diseases, metabolism, and anti-infectives. Leveraging its unique advantages in innovative drug development, the company now possesses over ten research and development pipelines, including monoclonal antibodies, bispecific antibodies, and ADC drugs. Biocytogen actively promotes independent and collaborative drug development. Currently, several self-developed antibody new drugs have entered clinical research. With the implementation of the large-scale antibody drug R&D plan "Thousands of Antibodies," the company will further focus on new drug R&D. In the future, the company will join hands with global partners to jointly accelerate the new drug R&D process. Biocytogen is headquartered in Beijing and has branches in Haikou, Jiangsu, Boston, USA, and Shanghai. Its wholly-owned subsidiary, Youhe Medicine, focuses on clinical development. Our Mission: Focus on technological innovation, continuous new drug output, and protect human health. Our Vision: Become a global source of new drugs.